Atreca to Cut About 40% of Workforce

marketwatch
2023-11-15

By Josh Beckerman

Biotechnology company Atreca said it is implementing a further reduction in its workforce of about 40% while maintaining the necessary support to continue exploring potential strategic transactions and business alternatives.

The company cited financial market conditions and the funding needs required to advance antibody-drug conjugate programs into clinical development.

Atreca also reported a third-quarter loss of 92 cents a share, compared with a loss of 60 cents a share a year earlier.

Write to Josh Beckerman at josh.beckerman@wsj.com

 

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10